Other preclinical studies provided rationale for MSA therapy with sodium phenylbutyrate, an unspecific histone deacetylase inhibitor tested in the PLP-α-Syn mice (Sturm et al. 2016), and benztropine, an anti-cholinergic drug acting on oligodendrocytes and enhancing re-myelination, tested in the MBP-α-Syn mice (Ettle et al. 2016). This evidence concerns the gene MBP and multiple system atrophy.